Treatment News : Drinking Coffee Doubles Hep C Treatment Responses

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » June 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

June 7, 2011

Drinking Coffee Doubles Hep C Treatment Responses

Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study published in the June 2011 issue of Gastroenterology. Patients who received pegylated interferon plus ribavirin treatment and who drank three or more cups of coffee per day were two times more likely to respond to treatment, compared with those who didn't drink coffee.

“Coffee intake has been associated with a lower level of liver enzymes, reduced progression of chronic liver disease and reduced incidence of liver cancer,” said Neal Freedman, PhD, MPH, of the National Cancer Institute and lead author of this study. “Although we observed an independent association between coffee intake and virologic response to treatment, this association needs replication in other studies.”
 
Among those who didn't drink coffee in the study, 46 percent had an early virologic response; 26 percent had undetectable HCV levels at week 20; 22 percent had undetectable virus at week 48; and 11 percent had a sustained virologic response (SVR). In contrast, the corresponding proportions for those who drank three or more cups of coffee per day were 73 percent, 52 percent, 49 percent and 26 percent, respectively.

Because patients in this particular study had previously failed interferon therapy, it is not clear whether the results can be generalized to other patient populations. Future studies among patients with less advanced disease, those who are first-time treatment takers, or who are being treated with newer antiviral agents are needed.


Search: coffee, hepatitis C, treatment, interferon, ribavirin, fibrosis, cirrhosis, SVR, cure


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.